Ulnar Neuropathy at Elbow
Conditions
Keywords
Ulnar Neuropathy at Elbow, platelet-rich plasma, Perineural injection
Brief summary
Ulnar neuropathy at elbow (UNE) is the second common peripheral entrapment neuropathy after carpal tunnel syndrome (CTS). Although many conservative managements of UNE were found, their effectiveness were often unsatisfied without existed guideline. Recently, the perineural injection of 5% dextrose wate (D5W) is a novel management for CTS but its effect for UNE is not obviously as CTS. Hence, it is very important to find another novel injectate for UNE.
Detailed description
The platelet-rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders and recent reports showed being beneficial for peripheral neuropathy in animal studies. Our previous research shown single injection with PRP was superior to D5W for CTS. However there is no study investigating the effect of PRP for UNE now. Hence, the purpose of this study was to assess the effect of perineural PRP injection for UNE.
Interventions
DRUGplatelet-rich plasma
Ultrasound-guided 3cc PRP injection between medial epicondyle and ulnar nerve
DRUG5% dextrose
Ultrasound-guided 3cc 5% dextrose injection between medial epicondyle and ulnar nerve
Sponsors
Yung-Tsan Wu
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age between 20-80 year-old. 2. Diagnosis as ulnar neuropathy at elbow at least one month
Exclusion criteria
1. Cancer 2. Coagulopathy 3. Pregnancy 3\. Any active infection status 4. Polyneuropathy of upper extremity 5. Brachial plexopathy 6. Thrombocytopenia Previously undergone wrist surgery or steroid injection for ulnar neuropathy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual analog scale (VAS) | Change from baseline at 6 month after injection | Digital pain severity or paresthesia/dysthesia was evaluated using VAS. Pain score scale ranged from 0 to 10, with 10 indicating the most severe pain. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disabilities of the Arm, Shoulder and Hand (DASH) | Change from baseline at 6 month after injection | Taiwan Disabilities of the Arm, Shoulder and Hand (DASH) contains 11-item disability/symptom scale and each item has five levels of response scoring from 1 to 5. The higher score means more disability or severer symptoms. |
| Electrophysiological study | Change from baseline at 6 month after injection | Nerve motor conduction velocity of the ulnar nerve before treatment and multiple time frame after treatment. |
| Cross-sectional area of ulnar nerve | Change from baseline at 6 month after injection | Using the musculoskeletal sonogram to measure the cross-sectional area of the ulnar nerve before treatment and multiple time frame after treatment. |
Countries
Taiwan
Outcome results
None listed